A Phase 1/Phase 2 Trial to Evaluate Safety, Immunogenicity and PSA Response of VTP-850 Prostate Cancer Immunotherapeutic in Men With Biochemical Recurrence After Definitive Local Therapy for Prostate Cancer
Latest Information Update: 12 Dec 2023
At a glance
- Drugs VTP-850 (Primary) ; VTP-850 (Primary) ; Checkpoint kinase inhibitors
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Barinthus Biotherapeutics
- 12 Jun 2023 According to a Vaccitech media release, the first phase of the trial is enrolling participants in the US, with plans to open further sites in Italy and Spain.
- 12 Jun 2023 According to a Vaccitech media release, a first patient has been dosed in this trial.
- 06 Jun 2023 The trial is open in the USA, with sites in Spain and Italy planned to open later in 2023, as per trial design presented at the 59th Annual Meeting of the American Society of Clinical Oncology.